Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy

Autor:	Stella S. Daskalopoulou, Grigorios Giamouzis, Ioannis Skoularigis, Apostolia Hatziefthimiou, Filippos Triposkiadis, Nikos Tsanaxidis, Isaac Aidonidis
Rok vydání:	2017
Předmět:	medicine.medical_specialty Ejection fraction Combination therapy business.industry medicine.medical_treatment Ranolazine Atrial fibrillation General Medicine 030204 cardiovascular system & hematology medicine.disease Cardioversion Amiodarone Loading dose 03 medical and health sciences 0302 clinical medicine Internal medicine Cardiology Medicine Sinus rhythm 030212 general & internal medicine Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Pacing and Clinical Electrophysiology. 40:372-378
ISSN:	0147-8389
DOI:	10.1111/pace.13048
Popis:	BACKGROUND Amiodarone (AMIO) is for many years effectively used to control ventricular rate during atrial fibrillation (AF) and to convert it into sinus rhythm. However, due to its delayed onset of action, ranolazine (RAN), a new antianginal agent with atrial-selective electrophysiologic properties, has recently been attempted as add-on therapy with AMIO to facilitate AF conversion. METHODS To establish the role of this combination therapy, we enrolled 173 consecutive patients (68 ± 10 years, 54% male) with recent-onset (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::aec6454bb0ad4828fa34056a157c49a7 https://doi.org/10.1111/pace.13048 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.